Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 In-vitro colorectal cancer screening tests industry 3600 synopsis, 2016 - 2027
2.1.1 Business trends
2.1.2 Test type trends
2.1.3 End-use trends
2.1.4 Regional trends
Chapter 3 In-Vitro Colorectal Cancer Screening Tests Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Improvements in colorectal cancer screening through non-invasive methods
3.3.1.2 Advancements in the field of cancer diagnosis
3.3.1.3 Rising prevalence of colorectal cancer
3.3.1.4 Cost-efficient and high-speed DNA sequencing
3.3.2 Industry pitfalls & challenges
3.3.2.1 Lack of uniform cancer screening guidelines in Asia Pacific
3.3.2.2 Inadequate reimbursement coverage
3.3.2.3 Shortage of trained staff in developing regions
3.4 Growth potential analysis
3.4.1 By test type
3.4.2 By end-use
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2020
3.7.1 Company matrix analysis, 2020
3.8 PESTEL analysis
Chapter 4 In-Vitro Colorectal Cancer Screening Tests Market, By Test Type
4.1 Key segment trends
4.2 Fecal occult blood test (FOBT)
4.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.2 Guaiac FOB stool test
4.2.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.3 Immuno-FOB agglutination test
4.2.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.4 Lateral flow immuno-FOB test
4.2.4.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.5 Immuno-FOB ELISA test
4.2.5.1 Market size, by region, 2016 – 2027 (USD Million)
4.3 Biomarker test
4.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.3.2 Tumor M2-PK stool test
4.3.2.1.1 Market size, by region, 2016 – 2027 (USD Million)
4.3.3 Transferrin assays
4.3.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.4 CRC DNA screening test
4.4.1 Market size, by region, 2016 - 2027 (USD Million)
4.4.2 Methylated gene test
4.4.2.1 Market size, by region, 2016 - 2027 (USD Million)
4.4.3 Panel DNA test
4.4.3.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 5 In-Vitro Colorectal Cancer Screening Tests Market, By End-use
5.1 Key segment trends
5.2 Hospitals
5.2.1 Market size, by region, 2016 – 2027 (USD Million)
5.3 Clinics
5.3.1 Market size, by region, 2016 – 2027 (USD Million)
5.4 Diagnostic laboratories
5.4.1 Market size, by region, 2016 – 2027 (USD Million)
5.5 Others
5.5.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 In-Vitro Colorectal Cancer Screening Tests Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market size, by country, 2016 - 2027 (USD Million)
6.2.2 Market size, by test type, 2016 - 2027 (USD Million)
6.2.2.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.2.2.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.2.2.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.2.3 Market size, by end-use, 2016 – 2027 (USD Million)
6.2.4 U.S.
6.2.4.1 Market size, by test type, 2016 - 2027 (USD Million)
6.2.4.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.2.4.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.2.4.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.2.4.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.2.5 Canada
6.2.5.1 Market size, by test type, 2016 - 2027 (USD Million)
6.2.5.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.2.5.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.2.5.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.2.5.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.3 Europe
6.3.1 Market size, by country, 2016 - 2027 (USD Million)
6.3.2 Market size, by test type, 2016 - 2027 (USD Million)
6.3.2.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.2.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.2.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.3 Market size, by end-use, 2016 – 2027 (USD Million)
6.3.4 Germany
6.3.4.1 Market size, by test type, 2016 - 2027 (USD Million)
6.3.4.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.4.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.4.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.4.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.3.5 UK
6.3.5.1 Market size, by test type, 2016 - 2027 (USD Million)
6.3.5.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.5.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.5.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.5.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.3.6 France
6.3.6.1 Market size, by test type, 2016 - 2027 (USD Million)
6.3.6.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.6.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.6.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.6.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.3.7 Spain
6.3.7.1 Market size, by test type, 2016 - 2027 (USD Million)
6.3.7.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.7.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.7.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.7.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.3.8 Italy
6.3.8.1 Market size, by test type, 2016 - 2027 (USD Million)
6.3.8.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.3.8.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.3.8.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.3.8.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Market size, by country, 2016 - 2027 (USD Million)
6.4.2 Market size, by test type, 2016 - 2027 (USD Million)
6.4.2.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.2.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.2.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.3 Market size, by end-use, 2016 – 2027 (USD Million)
6.4.4 China
6.4.4.1 Market size, by test type, 2016 - 2027 (USD Million)
6.4.4.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.4.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.4.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.4.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.4.5 Japan
6.4.5.1 Market size, by test type, 2016 - 2027 (USD Million)
6.4.5.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.5.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.5.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.5.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.4.6 India
6.4.6.1 Market size, by test type, 2016 - 2027 (USD Million)
6.4.6.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.6.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.6.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.6.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.4.7 Australia
6.4.7.1 Market size, by test type, 2016 - 2027 (USD Million)
6.4.7.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.7.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.7.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.7.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.4.8 South Korea
6.4.8.1 Market size, by test type, 2016 - 2027 (USD Million)
6.4.8.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.4.8.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.4.8.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.4.8.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.5 Latin America
6.5.1 Market size, by country, 2016 - 2027 (USD Million)
6.5.2 Market size, by test type, 2016 - 2027 (USD Million)
6.5.2.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.5.2.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.5.2.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
6.5.4 Brazil
6.5.4.1 Market size, by test type, 2016 - 2027 (USD Million)
6.5.4.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.5.4.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.5.4.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.5.4.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.5.5 Mexico
6.5.5.1 Market size, by test type, 2016 - 2027 (USD Million)
6.5.5.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.5.5.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.5.5.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.5.5.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.5.6 Argentina
6.5.6.1 Market size, by test type, 2016 - 2027 (USD Million)
6.5.6.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.5.6.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.5.6.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.5.6.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.6 Middle East and Africa
6.6.1 Market size, by country, 2016 - 2027 (USD Million)
6.6.2 Market size, by test type, 2016 - 2027 (USD Million)
6.6.2.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.6.2.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.6.2.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
6.6.4 South Africa
6.6.4.1 Market size, by test type, 2016 - 2027 (USD Million)
6.6.4.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.6.4.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.6.4.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.6.4.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.6.5 Saudi Arabia
6.6.5.1 Market size, by test type, 2016 - 2027 (USD Million)
6.6.5.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.6.5.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.6.5.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.6.5.2 Market size, by end-use, 2016 – 2027 (USD Million)
6.6.6 UAE
6.6.6.1 Market size, by test type, 2016 - 2027 (USD Million)
6.6.6.1.1 Market size, by fecal occult blood test (FOBT), 2016 - 2027 (USD Million)
6.6.6.1.2 Market size, by biomarker test, 2016 - 2027 (USD Million)
6.6.6.1.3 Market size, by CRC DNA screening test, 2016 - 2027 (USD Million)
6.6.6.2 Market size, by end-use, 2016 – 2027 (USD Million)
Chapter 7 Company Profiles
7.1 Competitive dashboard, 2020
7.2 Abbott Molecular
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Epigenomics AG
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Sysmex Corporation
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 Eiken Chemical
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Quest Diagnostics
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 OncoCyte Corporation-Bio time
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 BioMarCare Technologies
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 Novigenix
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 Strategic outlook
7.9.5 SWOT analysis
7.10 Randox Laboratories
7.10.1 Business overview
7.10.2 Financial data
7.10.3 Product landscape
7.10.4 Strategic outlook
7.10.5 SWOT analysis
7.11 Exact Sciences Corporation
7.11.1 Business overview
7.11.2 Financial data
7.11.3 Product landscape
7.11.4 Strategic outlook
7.11.5 SWOT analysis
7.12 Immunostics
7.12.1 Business overview
7.12.2 Financial data
7.12.3 Product landscape
7.12.4 Strategic outlook
7.12.5 SWOT analysis
7.13 R-Biopharm Incorporation
7.13.1 Business overview
7.13.2 Financial data
7.13.3 Product landscape
7.13.4 Strategic outlook
7.13.5 SWOT analysis
